Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts

On Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported third-quarter adjusted EPS of $0.16, down from $0.19 a year ago, beating the consensus of $0.14.

The company reported sales of $702.47 million, up 13% year-over-year, beating the consensus of $696.80 million.

Generic net revenue increased by 9% to $427.35 million, driven by the strong performance of new product launches and biosimilars.

Specialty net revenue increased 19% to $115.64 million, driven by promoted products in neurology and endocrinology, including the recent launches of CREXONT and ONGENTYS for Parkinson’s disease.

AvKARE’s net revenue increased by 21% to $159.49 million, ...

Full story available on Benzinga.com